Latest market price
8.33
-0.32-3.70%
OverviewShort InterestFilings
CADLQT73Candel Therapeutics, Inc.·NASDAQ
8.33-3.70%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-1.41Insider Own9.98%Shs Outstand76.52MPerf Week3.74%
Market Cap637.40MForward P/E—EPS next Y-1.11Insider Trans-4.16%Shs Float60.22MPerf Month-18.01%
Enterprise Value484.40MPEG—EPS next Q-0.35Short Float21.21%Perf Quarter-17.28%
Income-88.00MP/S—EPS this Y—Short Ratio11.00Perf Half Y28.75%
Sales0.00P/B5.06EPS next Y—ROA-42.53%Short Interest12.77MPerf YTD47.43%
Book/sh1.65P/C3.16EPS next 5Y—ROE-89.38%52W High14.00 -40.50%Perf Year51.73%
Cash/sh2.64P/FCF—EPS past 3/5Y—ROIC-36.74%52W Low4.35 91.49%Perf 3Y835.96%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility6.74% 5.60%Perf 5Y-13.50%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.57Perf 10Y—
Dividend Ex-Date—Quick Ratio16.09Sales Y/Y TTM—Profit Margin0.00%RSI (14)37.70Recom2.00
Dividend Gr. 3/5Y—Current Ratio16.09EPS Q/Q-477.78%SMA20-6.44%Beta-0.21Target Price23.33
Payout0.00%Debt/Eq0.39Sales Q/Q—SMA50-22.01%Rel Volume0.68Prev Close8.65
Employees55LT Debt/Eq0.39EarningsNov 12SMA2000.58%Avg Volume1.14MPrice8.33
IPO DateJul 27, 2021Option/ShortYes / YesEPS/Sales Surpr.-118.55% —Net Debt/EBITDA—Volume779,157Change-3.70%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-22-26InitiatedJefferiesBuy$25
Sep-21-26UpgradeB of A SecuritiesNeutral → Buy
Jul-29-26ReiteratedH.C. WainwrightBuy$23
Jul-13-26InitiatedStifelBuy$22
Oct-27-25InitiatedStephensOverweight$15
Sep-03-25DowngradeB of A SecuritiesBuy → Neutral
Latest News· Times ET
Oct-29-26
Oct-29-2609:00AM
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancerglobenewswire.com
05:08AM
Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual MeetingBenzinga
Oct-27-26
Oct-27-2608:05AM
Candel Therapeutics to Present at November Investor Conferencesglobenewswire.com
Oct-22-26
Oct-22-2608:05AM
Candel Therapeutics Appoints Maria Ostrovsky as General CounselYahoo
Oct-02-26
Oct-02-2609:00AM
Candel Therapeutics to Present at the SITC 2026 Annual Meetingglobenewswire.com
Oct-01-26
Oct-01-2604:05PM
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
08:05AM
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICIglobenewswire.com
Sep-30-26
Sep-30-2608:30AM
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancerglobenewswire.com
08:05AM
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026globenewswire.com
04:33AM
Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate CancerBenzinga
Sep-22-26
Sep-22-2602:50PM
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4seekingalpha.com
Sep-16-26
Sep-16-2605:47AM
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and JanuxYahoo
Sep-15-26
Sep-15-2611:15AM
4 Prostate Cancer Drug Stocks to Watch During Awareness Monthzacks.com
Sep-10-26
Sep-10-2608:05AM
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directorsglobenewswire.com
Sep-01-26
Sep-01-2604:05PM
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Company

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
0000————
Cost of Goods Sold Incl. D&A
0000————
Gross Profit
0000————
Selling, General and Administrative Excl. Other23181414————
Research and Development49301925————
Other Operating Expense000-1————
Operating Income-72-48-33-38————
Interest Expense5223————
Unusual Expense
————————
Non-Operating Income (Expense)-1212-203————
Net Income Before Taxes-88-38-55-38————
Income Taxes
0000————
Consolidated Net Income-88-38-55-38————
Net Income From Continuing Operations-88-38-55-38————
Net Income-88-38-55-38————
EPS (Recurring)-1.41-0.72-1.74-1.31————
EPS (Basic, Before Extraordinaries)-1.41-0.72-1.74-1.31————
EPS (Diluted)-1.41-0.72-1.74-1.31————
EBITDA-83-35-52-34————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio
————————
Gross Margin
————————
Operating Margin
————————
Net Margin
————————
Shares Outstanding74533229————
Market Capitalization61629927843————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$15.15$12.12$9.09$6.05$3.02● Close Price0.00M0.79M1.58M2.37M3.16MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Tak Paul PeterChief Executive OfficerSep 11 '26Sale10.4659,379620,891113,321Sep 11
Tak Paul PeterChief Executive OfficerSep 10 '26Option Exercise1.55125,000193,750393,566Sep 11
Tak Paul PeterChief Executive OfficerSep 10 '26Sale11.50220,8662,539,893172,700Sep 11
Tyagarajan SeshuChief Technology OfficerAug 17 '26Sale12.007,00084,00076,865Aug 19
Tyagarajan SeshuChief Technology OfficerJun 29 '26Sale10.027,00070,15183,865Jul 01
Barone FrancescaChief Scientific OfficerJun 29 '26Sale10.0623,447235,76977,362Jul 01
Manning Paul BDirectorFeb 23 '26Buy5.45550,4582,999,9962,763,527Feb 26
Nichols William GarrettChief Medical OfficerJul 28 '25Option Exercise1.299371,20953,430Jul 30
Nichols William GarrettChief Medical OfficerJul 28 '25Sale6.989376,54052,493Jul 30
Nichols William GarrettChief Medical OfficerJun 30 '25Option Exercise1.297811,00753,274Jul 02
Nichols William GarrettChief Medical OfficerJun 30 '25Sale5.047813,93652,493Jul 02
Tak Paul PeterChief Executive OfficerMar 19 '25Sale9.004003,601225,740Mar 20
Barone FrancescaChief Scientific OfficerMar 18 '25Option Exercise1.5518,00027,900128,673Mar 20
Nichols William GarrettChief Medical OfficerMar 18 '25Option Exercise1.9018,48935,12797,809Mar 20
Nichols William GarrettChief Medical OfficerMar 18 '25Sale8.7645,316396,99552,493Mar 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.